

NCRO HIGHLIGHTS

**Duke
Neuroscience**

Neuroscience Clinical Research Organization

Division of Neurology
Department of Medicine
Duke University Health System



November 2005

The mission of the NCRO is to foster the development of a world-class neuroscience clinical trials center.

Who's Who in the NCRO

Management	Coordination	Email:
Mark Stacy, Medical Director	Kate Beck 668-2278	beck0002@mc.duke.edu
Carmelo Graffagnino, Co-Medical Director	Gail Cook 684-0865	cook0007@mc.duke.edu
Ron Beauvais, Administrator	Joanne Field 668-2842	joanne.field@duke.edu
Donna Carnes, Regulatory Assistant	Karen Grace 668-2844	karen.grace@duke.edu
Lisa Gauger, Clinical Research Administrator	Debra Heydt 668-2843	debra.heydt@duke.edu
JoAnn Jones, Regulatory Administrator	Rene Link 970-1648	link0002@mc.duke.edu
	Sarah Wyne 668-2837	wyn0001@mc.duke.edu

We would like your suggestions for topics in future issues of the NCRO Newsletter! Please send your suggestions to: JoAnn Jones @ jones018@mc.duke.edu.

ACTIVE ENROLLING STUDIES

The NCRO currently supports **39** active studies. This list includes only those studies that are actively enrolling. Please help us reach our targets (column 6).

DEMENTIA STUDIES

PI	SPONSOR	INDICATION	STUDY-ID	COORDINATOR	TARGET / # PTS ENROLLED-11/30/05
BURKE, Jim	GlaxoSmithKline	Mild to Moderate AD	Rosiglitazone XR	Heydt 668-2843	15 / 9
WHITE, Heidi	NIH	Mild cog. Impairment	Nicotine Tr of MCI	Cook 684-0865	25 / 14

EPILEPSY

HUSAIN, Aatif	Schwarz	Epilepsy-partial seizures	SPM 927 (SP 754)	Beck 668-2278	5 / 8
---------------	---------	---------------------------	------------------	---------------	-------

MOVEMENT DISORDERS

MORGENLANDER, J	Private Investors	Restless Legs	RLS	N/A	20 / 16
SCOTT, Burt	Physician Funded	Movement disorder	Visual Documentation	N/A	No Target / 464
SCOTT, Burt	Physician Funded	Movement disorder	Tetrabenazine	N/A	No Target / 54
SCOTT, Burt	Wyeth Pharm	PD-post-menopausal women	POETRY	Gauger 668-1538	5 / 6
SCOTT, Burt	Boston Life Sciences	Tremor	Altropane	Wyne 668-2837	20 / 7
STACY, Mark	Novartis	PD requiring levodopa	Stride PD (Stalevo)	Beck 668-2278	15 / 15
STACY, Mark	Inst Neurodeg Disorder	Early PD	SPECT imaging	Gauger 668-1538	8 / 2
STACY, Mark	Boehringer Ingelheim	PD eye safety study	Pramipexole vs. Ropinirole	Field 668-2842	10 / 0

NEUROMUSCULAR

BEDLACK, Rick	Columbia / NINDS	ALS	Minocycline	Grace 668-2844	15-20 / 19
---------------	------------------	-----	-------------	----------------	------------

VASCULAR

GOLDSTEIN, Larry	AGA Med Corp	Cryptogenic stroke	RESPECT	Link 970-1648	10 / 17
GOLDSTEIN, Larry	Boehringer Ingelheim	Recurrent strokes	PRoFESS	Link 970-1648	30 / 11
GRAFFAGNINO, C	NIH / Wash Univ	Carotid occlusion	Surgery vs stan med care	Stoner 668-5275	30 / 2
GRAFFAGNINO, C	AstraZeneca-	Acute ischemic stroke	Stroke-SA-NXY-0007	Stoner 668-5275	10 / 10
GRAFFAGNINO, C	AstraZeneca	Acute ICH	CHANT-SA-NXY-0012	Stoner 668-5275	3-6 / 2
GRAFFAGNINO, C	Novo Nordisk	Acute intracerebral hemorrhage	F7ICH-1641	Stoner 668-5275	5 / 0
LASKOWITZ, Danny	Biosite	Biomarker-brain injury	Triage Stoke Panel	B. Blessing 970-4888	450 / 546
LASKOWITZ, Danny	Merck & Phys Funded	Aneurismal SAH	Simvastatin-SAH	B. Blessing 970-4888	120 / 51
LYNCH, John	Physician Funded	Traumatic brain injury	Simvastatin-TBI	B. Blessing 970-4888	100 / 6

NCRO Trials Completed in 2005

Burke – MCI Biomarker with GSK	Scott – Precept with Cephalon
Graffagnino – AbESTT II with Centocor	Scott – Net PD Minority Task Force
Husain – RLS 248.543 with Boehringer Ingelheim	Scott – 168 with GlaxoSmithKline
Massey – CD 191622-017 with Allergan	Stacy – 169 with GlaxoSmithKline
Scott – Net PD FS-T00	Stacy – Feasibility Diary Study with Merck
Scott – Net PD FS1	

**Duke University School of Medicine
Clinical Trials Quality Assurance (CTQA)
LUNCH AND LEARN SERIES
2005/2006 Schedule**

The lunch and learn series are one hour [coordinator centric educational sessions](#) with the primary goal of providing useful, hands on knowledge to build a stronger research work force. These sessions will also provide the members of the CTQA office an opportunity to present themselves as a resource to the research community.

December 8	AE Reporting	Ken Mahaffey
January 16	Clinical Trials Billing	Donna Morris
February 6	Investigational Drug Service	Sharon Ellison, R.Ph.
March 20	Clinical Trials Litigation	Kim Wilson, J.D.
April 6	TBD	TBD
May 12	Humanitarian Use Devices	John Falletta, M.D.
June 6	TBD	TBD

THE CTQA LUNCH AND LEARN SERIES IS FREE AND OPEN TO THE PUBLIC – DUKE UNIVERSITY HEALTH SYSTEM AFFILIATION IS NOT REQUIRED. SEATING IS ON A FIRST COME, FIRST SERVED BASIS FOR THOSE WHO HAVE REGISTERED FOR THE SERIES.

ALL SESSIONS ARE SCHEDULED FOR 12:00-1:00 PM IN ROOM 103 OF THE BRYAN RESEARCH BUILDING (NOT THE BRYAN CENTER). **SESSIONS HAVE BEEN APPROVED FOR 1.2 NURSING CONTACT HOURS AND 1.0 CONTINUING EDUCATION UNITS.**

PLEASE REGISTER FOR THE SERIES BY E-MAILING CTQA@MC.DUKE.EDU
BRING YOUR LUNCH, THE COMPLIANCE OFFICE WILL PROVIDE DRINKS AND DESSERTS!!

******NCRO Advisory Board Meeting******

The next NCRO Advisory Board (AB) meeting is scheduled for January 11, 2006 in the 2nd floor conference room at Morreene Road Clinic at 5:30 p.m. Because of increasing emphasis on fiscal responsibility, the AB may have to make decisions regarding discontinuing poorly-enrolling trials or no longer accepting new trials. If you have a low enrolling trial or potentially new trial, consider contacting an AB member prior to this important meeting.

**The NCRO Staff would like to thank you for your support in the past year.
We would like to extend a Merry Christmas and Happy Holiday Season to
all of you and best wishes for the New Year.**

